Noreen Shah Hassan

US Patent:

20130004563, Jan 3, 2013

Filed:

Jun 6, 2012

Appl. No.:

13/489936

Inventors:

SYED SHAH - Delray Beach FL, US
NOREEN HASSAN - BOCA RATON FL, US

International Classification:

A61K 9/14
A61P 25/24
A61P 19/08
B05D 5/00
A61P 25/00
A61P 1/16
A61K 9/48
A61K 31/7076
A61P 19/02

US Classification:

424451, 424494, 514 46, 424495, 427 221

Abstract:

Multiparticulate compositions having S-adenosylmethionine an active ingredient are disclosed. The multiparticulates have spheroidal core comprising S-adenosylmethionine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

US Patent:

20120315337, Dec 13, 2012

Filed:

Jun 6, 2012

Appl. No.:

13/490144

Inventors:

Syed Shah - Delray Beach FL, US
Noreen Hassan - Boca Raton FL, US

International Classification:

A61K 31/405
B05D 7/00
A61K 9/16

US Classification:

424494, 514419, 427 221

Abstract:

Enteric coated multiparticulate compositions that use 5-HTP as an active ingredient are disclosed. The multiparticulates have a spheroidal core comprising 5-HTP, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methylcellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

US Patent:

20120315326, Dec 13, 2012

Filed:

Jun 6, 2012

Appl. No.:

13/490198

Inventors:

Syed SHAH - Delray Beach FL, US
Noreen HASSAN - Boca Raton FL, US

International Classification:

A61K 31/205
A61K 31/221
A61K 9/48
A61P 9/00
B05D 7/00
A61P 9/04
A61P 13/12
A61P 25/28
A61P 31/18
A61P 15/00
A61K 9/14
A61P 9/10

US Classification:

424451, 424494, 514556, 424495, 514547, 427 221

Abstract:

Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

US Patent:

20200253882, Aug 13, 2020

Filed:

May 1, 2020

Appl. No.:

16/864715

Inventors:

- Boca Raton FL, US
Noreen Hassan - Boca Raton FL, US

International Classification:

A61K 9/50
A61K 31/225
A61K 31/205
A23L 33/175
A23P 10/30

Abstract:

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

US Patent:

20180369157, Dec 27, 2018

Filed:

Sep 4, 2018

Appl. No.:

16/121245

Inventors:

- Boca Raton FL, US
Noreen Hassan - Boca Raton FL, US

International Classification:

A61K 9/50
A61K 31/225
A61K 31/205
A23P 10/30
A23L 33/175

Abstract:

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

US Patent:

20170231940, Aug 17, 2017

Filed:

May 4, 2017

Appl. No.:

15/586652

Inventors:

- Boca Raton FL, US
Noreen Hassan - Boca Raton FL, US
Christopher Diorio - Boca Raton FL, US
Fred Hassan - Boca Raton FL, US

Assignee:

Physician's Seal, LLC - Boca Raton FL

International Classification:

A61K 31/205
A61K 45/06
A61K 31/198
A61K 9/16
A61K 31/7068

Abstract:

A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and/or cognitive impairment.

US Patent:

20140370112, Dec 18, 2014

Filed:

Sep 3, 2014

Appl. No.:

14/476152

Inventors:

- Boca Raton FL, US
Noreen Hassan - Boca Raton FL, US

International Classification:

A61K 9/50
A61K 31/225

US Classification:

424494, 424490, 424497, 514547

Abstract:

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.